Safety of Radioembolization in the Setting of Angiographically Apparent Arterioportal Shunting

Thornton, L.; Geller, Brian; Pepin, Eric W.; Shah, Jessica; Kapp, M.; Toskich, Beau B.

doi:10.1016/j.jvir.2018.06.012

Cited by 7 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When the arterioportal shunt is limited to the target lobe, TARE can be safely performed in most cases. 10 However, when the arterioportal shunt reaches the contralateral lobar portal vein, it is a relative contraindication for TARE. On CT and magnetic resonance imaging (MRI) of the hepatic arterial phase, intense contrast enhancement of the portal vein indicates the presence of an arterioportal shunt.…”

Section: Patient Selectionmentioning

confidence: 99%

Radioembolization for hepatocellular carcinoma: what clinicians need to know

Choi

Kim

2022

J Liver Cancer

View full text Add to dashboard Cite

Transarterial radioembolization (TARE) with yttrium 90 ( 90 Y) has been used in the management of hepatocellular carcinoma (HCC) for more than 10 years in Korea. There are two types of 90 Y radioactive microspheres available, namely, glass and resin microspheres, with comparable clinical outcomes. In general, TARE outperforms transarterial chemoembolization regarding post-embolization syndrome, time to progression, tumor downsizing for liver transplantation, and hospitalization stay. Although TARE is commonly recommended for patients with unresectable large HCCs, it can be an alternative to or performed in combination with ablation, surgical resection, and systemic treatment. This review aimed to address 90 Y radioactive microspheres, patient selection, clinical outcomes, simulation tests, radioembolization procedures, follow-up imaging, and complications.

show abstract

Section: Patient Selectionmentioning

confidence: 99%